Abstract
HBV reactivation could occur in HBV-related HCC patients who treated with TACE in combination with TKIs plus ICIs. Before and during the combination treatment, it is necessary to routinely monitor HBV DNA and to take effective prophylactic antiviral therapy.
Introduction
Hepatocellular carcinoma (HCC) remains a significant global health burden, often stemming from chronic Hepatitis B Virus (HBV) infection. For patients with advanced, unresectable HCC, clinical practice has shifted toward aggressive combination therapies. A prominent "triple threat" approach involves Transarterial Chemoembolization (TACE), Tyrosine Kinase Inhibitors (TKIs), and Immune Checkpoint Inhibitors (ICIs).
While this combination enhances anti-tumor efficacy, it introduces complexities regarding viral management. Immunotherapy, in particular, can disrupt the immune balance in the liver, potentially triggering the reactivation of latent HBV. Such reactivation can lead to severe hepatitis, liver failure, or even death. This study, published in Frontiers in Cellular and Infection Microbiology, investigates the incidence and risk factors of HBV reactivation in patients undergoing this specific triple therapy and evaluates its impact on overall survival.
Methods
The researchers conducted a retrospective study at the Affiliated Hospital of Xuzhou Medical University, analyzing a cohort of 119 patients with HBV-related advanced HCC. These patients received the combination of TACE, TKIs, and ICIs between January 2020 and December 2021.
HBV reactivation was defined according to the Asian-Pacific Association for the Study of the Liver (APASL) guidelines, which include criteria such as a 100-fold increase in HBV DNA or seroconversion from HBsAg-negative to positive. The study utilized logistic regression to pinpoint independent risk factors and the Kaplan-Meier method to assess survival outcomes.
Results
The study observed an HBV reactivation rate of 10.1% (12 out of 119 patients). Interestingly, the analysis revealed a "clinical paradox": patients with undetectable HBV DNA at baseline were at a significantly higher risk for reactivation (OR=0.073, $P=0.026$). This is likely because patients with detectable viral loads are routinely prescribed prophylactic antiviral therapy, whereas those with undetectable levels may be overlooked, leaving them vulnerable to the immunosuppressive effects of the triple therapy.
The median survival time (MST) for the entire cohort was 22.4 months. Crucially, the occurrence of HBV reactivation did not significantly impact survival. As shown in Figure 2B, the MST for the reactivation group was "undefined" (as more than half the patients survived the study period), compared to 22.4 months in the non-reactivation group ($P=0.614$). This survival neutrality is attributed to the timely administration of antiviral drugs once reactivation was detected.
Discussion and Conclusion
The findings underscore that triple therapy for HCC carries a higher risk of HBV reactivation (10.1%) than immunotherapy alone. The lack of prophylactic antiviral treatment was identified as a primary independent risk factor (OR=0.047, $P=0.001$).
While the study is limited by its retrospective nature and single-center design, it provides vital clinical guidance. Clinicians must not assume that "undetectable" baseline viral loads equate to safety. Routine HBV DNA monitoring and proactive antiviral prophylaxis are essential components of managing advanced HCC patients undergoing combination therapy to prevent potentially fatal viral flares. Future multi-center prospective trials are needed to refine these protocols and compare the efficacy of different antiviral agents in this high-risk population.
Summary updated